About Gossamer Bio
Gossamer Bio (NASDAQ:GOSS) is a biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics in the areas of immunology, inflammation, and oncology. With a focus on addressing unmet medical needs, Gossamer Bio is actively advancing a diverse portfolio of clinical and preclinical projects aimed at providing new treatment options for patients. The company's objectives are to leverage its scientific expertise and operational efficiency to bring novel therapies from the laboratory to the clinic as swiftly and safely as possible. Through strategic collaborations and a commitment to research excellence, Gossamer Bio strives to improve health outcomes and enhance the quality of life for people around the globe.
Snapshot
Operations
Produtos e/ou serviços de Gossamer Bio
- Serabelisib, a PI3K delta inhibitor targeting hematologic malignancies.
- GB001, an oral DP2 antagonist for asthma and chronic rhinosinusitis.
- GB002, an inhaled PDGFR inhibitor for pulmonary arterial hypertension.
- GB004, an oral HIF-1 alpha stabilizer for ulcerative colitis.
- GB1275, an oral CD11b modulator for oncology indications.
- Research and development services focusing on innovative therapies for immunology, inflammation, and oncology.
equipe executiva do Gossamer Bio
- Mr. Faheem HasnainCo-Founder, CEO, President & Chairman
- Mr. Bryan GiraudoCOO & CFO
- Dr. Richard Aranda M.D.Chief Medical Officer
- Mr. Christian Waage J.D.Executive Vice President of Technical Operations & Administration
- Mr. Jeff BoernekeGeneral Counsel & Secretary
- Ms. Jeanine AnthonySenior Vice President of Marketing
- Ms. Deanna WeberExecutive Vice President of Human Resources
- Dr. Robert F. Roscigno Ph.D.Senior Vice President of Clinical Development of Pulmonary Vascular Disease
- Ms. Caryn L. PetersonExecutive Vice President of Regulatory Affairs
- Mr. Matt CravetsSenior Vice President of Biometrics